

# CLINICAL RESEARCH OUR STATEMENT OF INTENT

## STATEMENT OF INTENT

We will maintain a **broad portfolio** that maximises **patient impact**

We will learn **as much as we can** from the patients on our trials

## SUPPORTING STATEMENTS

Support a broad portfolio of clinical research that includes a range of **modalities** and **disease sites**, including rare cancers, and maximises patient impact

Prioritise investment in trials studying **CRUK Cancers of Unmet Need**

Support a balance of trials conducted in **early, pre-invasive, localised disease and metastatic** settings in order to improve patient outcomes

Invest more in promising, high impact, innovative **early phase** and **first-in-man** trials that would not progress otherwise

Act decisively as we **proactively manage** our portfolio

Seek opportunities to build and leverage commercial partnerships that accelerate the development of innovative **treatments and research**

Prioritise our investment into scientifically-driven studies that use and analyse biomarkers and imaging, producing valuable **biological and clinical information** that will optimise treatments

Prioritise hypothesis-driven, data-rich, **sample collections** that support the discovery, validation and qualification of valuable biological information

Grow investment in **innovative, cost-effective trial designs** (e.g. basket trials, umbrella protocols, adaptive trials) that can be supported by strategic long-term investments in trial platforms

Encourage investigators to innovate, and selectively **accept greater scientific uncertainty** in trials where potential impact is high<sup>1</sup>

<sup>1</sup> Examples include (i) CDD's first-in-class experimental medicine trial (Mov18 IgE trial) where the target is not new (folate receptor) but it is the first time an IgE class antibody has been tested for cancer therapy, and (ii) using targeted therapies in early stage cancers when there are likely to be less driver mutations to target